Properties (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiretroviral drug
|
| gptkbp:activeDuring |
tipranavir
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableIn |
generic version
|
| gptkbp:clinicalTrials |
Phase III
effective in treatment-experienced patients |
| gptkbp:contraindication |
severe liver disease
allergy to tipranavir |
| gptkbp:developedBy |
gptkb:Boehringer_Ingelheim
|
| gptkbp:dosageForm |
oral
|
| gptkbp:drugInterdiction |
available online
protease inhibitor |
| gptkbp:formulation |
tablet
|
| gptkbp:hasCapacity |
educational resources available
support groups available available through patient assistance programs treatment adherence counseling available |
| gptkbp:healthcare |
take with food
do not skip doses consult doctor before stopping |
| https://www.w3.org/2000/01/rdf-schema#label |
Aptivus
|
| gptkbp:interactsWith |
other antiretrovirals
certain antibiotics antifungal medications anticonvulsants |
| gptkbp:is_monitored_by |
liver function tests
viral load CD4 count |
| gptkbp:issuedBy |
oral tablet
|
| gptkbp:isUsedFor |
ritonavir
|
| gptkbp:lastProduced |
2005
|
| gptkbp:marketedAs |
gptkb:Aptivus
|
| gptkbp:packaging |
bottle
|
| gptkbp:patentExpiration |
2023
|
| gptkbp:research |
studies on combination therapies
studies on pediatric use ongoing studies for new formulations studies on long-term effects studies on drug resistance |
| gptkbp:safetyFeatures |
risk of liver problems
risk of pancreatitis risk of allergic reactions risk of bleeding risk of cardiovascular events risk of diabetes risk of drug interactions risk of hyperlipidemia risk of immune reconstitution syndrome risk of lactic acidosis risk of opportunistic infections |
| gptkbp:sideEffect |
fatigue
headache nausea diarrhea |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
inhibits HIV protease
|
| gptkbp:usedFor |
treating HIV
|